SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 18, 2019. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM. The filing reports a material definitive agreement and corporate announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a strategic corporate announcement rather than financial performance data.
Material Changes
On November 18, 2019, the Company announced its support for the launch of the Alliance for Advancing Bioelectronic Medicine (AABM). The AABM is described as an independent network of professionals united to support bioelectronic medicine. This event is reported under Item 8.01 (Entry Into a Material Definitive Agreement).
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) detailing the AABM launch but does not contain specific financial guidance, forward-looking projections, or a discussion of risks and contingencies within the body of this 8-K. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 to understand the specific commitments made to the AABM.
- Confirm the Company's current financial status via the most recent 10-K or 10-Q, as this 8-K contains no financial data.
- Monitor future filings for any financial impact or revenue recognition related to the AABM partnership.
- Note the discrepancy between the requested company name (Streamex Corp.) and the actual registrant (BioSig Technologies, Inc.).